FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the ...
Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A .
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside ...
Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
Animals depend on their sense of smell to locate food, identify mates and evade danger. In mammals, olfactory perception typically relies on G protein–coupled receptor (GPCR) pathways. Insects, by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results